Drug Safety Information for TEKTURNA (Aliskiren hemifumarate)

FDA Safety-related Labeling Changes for TEKTURNA (ALISKIREN HEMIFUMARATE) Rx Drug: Safety Information Link

FDA Safety-related Labeling Changes for TEKTURNA HCT (ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE) Rx Drug: Safety Information Link

FDA Safety-related Labeling Changes for TEKAMLO (ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE) Discontinued Drug: Safety Information Link

FDA Safety-related Labeling Changes for AMTURNIDE (ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE) Discontinued Drug: Safety Information Link

Adverse Drug Reactions for TEKTURNA* (Aliskiren hemifumarate)

These charts and graphs are based on reports received through the FDA Adverse Event Reporting System (FAERS) program (see below).

Top 20 Adverse Effects Associated with TEKTURNA
(reported in FDA Medwatch/FAERS Reports)

  Side Effect # of FDA Reports
1Blood pressure increased269
2Dyspnoea*268
3Dizziness*265
4Hypertension253
5Drug ineffective233
6Diarrhoea*200
7Blood creatinine increased197
8Fatigue188
9Hypotension181
10Headache*181
11Oedema peripheral178
12Nausea165
13Blood pressure inadequately controlled138
14Cerebrovascular accident135
15Asthenia135
16Angioedema129
17Cough*128
18Renal failure127
19Malaise124
20Cardiac failure119

* This side effect also appears in "Top 10 Side Effects of TEKTURNA " in the drug's Review Summary based on AskaPatient reviews.

Top 10 Reasons for Taking TEKTURNA
(associated with FDA Medwatch/FAERS Reports)

Reason # of FDA Reports
1Hypertension*5260
2Cardiac failure1133
3Product used for unknown indication818
4Cardiovascular disorder374
5Blood pressure*340
6Cardiac failure acute238
7Essential hypertension208
8Acute myocardial infarction124
9Blood pressure abnormal78
10Blood pressure increased67

*Also a top-10 reason in AskaPatient Review Summary.


Types of Adverse Events for TEKTURNA

Total Reports Filed with FDA: 15836


Number of FDA Adverse Event Reports by Patient Age for TEKTURNA

Total Reports Filed with FDA: 15836*


* Reports for drugs with the same active ingredients have been aggregated in this analysis: Aliskiren hemifumarate (Tekturna)

Charts are based on 15836 reports filed with the FDA between 2004 and June 2015.

Adverse Event Reports are submitted to the FDA by pharmaceutical companies (mandatory reporting is required by manufacturers, distributors, or importers), health care providers such as doctors (voluntary reporting), and by patients themselves (voluntary reporting). More Information on FDA MedWatch (FDA Safety Information and Adverse Event Reporting Program)Voluntary reporting takes place under the FDA's MedWatch program, where health care professionals and consumers submit reports to FDA when they find a problem with a drug, medical device, biologic, or other FDA-regulated product. An adverse event is any undesirable experience or extreme side effect associated with the use of a medical product. Adverse events include: death, life threatening event, hospitalization, disability or permanent damage, congenital anomaly or birth defect, medical product use requiring a surgical or other intervention, or other serious medical situation believed to be caused by the drug.

Click to go back to search results and TEKTURNA Reviews and Review Summary .

Historical Analytics of FDA Adverse Event Reports Provided by Druginformer.com. FDA Drug Safety Information, including safety-related labeling updates, required post-approval safety studies, risk evaluation management strategies (REMS), alerts, and recalls are compiled by AskaPatient.com from the U.S. Food and Drug Administration.